Real-world evidence on treatment patterns and survival among ALK+ NSCLC patients in Canada who discontinue crizotinib treatment

Category Primary study
JournalJournal of Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: b5e6fdb0a5d33c3379a138b5124aa6b66e869b4d
First added on: Feb 07, 2025